

## Learning Objectives

*After completing this activity, the participant should be better able to*

- Explain the role of multiplexed gene sequencing platforms and next-generation sequencing testing in tailoring effective treatments to individual NSCLC patients
- Outline the clinical data supporting the optimal use of MET, EGFR and ALK inhibitors in the treatment of NSCLC
- Outline the clinical data supporting the optimal use of immunotherapy options for treatment of NSCLC
- Identify strategies and challenges due to secondary or acquired EGFR TKI resistance
- Identify the role of personalized maintenance therapy in patients with the nonsquamous NSCLC
- Update on optimal prioritization and integration of therapies with standard chemotherapy and concurrent chemoradiation for recurrent and/or metastatic SCCHN
- Identify and utilize molecular targets and integration of targeted therapies for recurrent and/or metastatic SCCHN
- Describe the role of molecular markers and prognostic biomarkers in the treatment of head & neck cancer
- Evaluate the emerging treatments options in the management of radioactive iodine-resistant differentiated thyroid cancer
- Interpret and apply data from clinical trials and translation in clinical practice on multi-targeted tyrosine kinase inhibitors for medullary and differentiated thyroid cancer